HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
HCW Biologics Inc. (HCWB)
Company Research
Source: GlobeNewswire
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced the first patient was dosed at The Ohio State University Wexner Medical Center for the Company-sponsored, multi-center first-in-human clinical trial to evaluate HCW9302 in patients with alopecia areata (NCT07049328). This marks a major milestone in the Company’s clinical development program in autoimmun
Show less
Read more
Impact Snapshot
Event Time:
HCWB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCWB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCWB alerts
High impacting HCW Biologics Inc. news events
Weekly update
A roundup of the hottest topics
HCWB
News
- HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- HCW Biologics GAAP EPS of -$2.02, revenue of $15.60M [Seeking Alpha]Seeking Alpha
- HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial ResultsGlobeNewswire
- HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewswire
- HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingGlobeNewswire
HCWB
Sec Filings
- 11/20/25 - Form 8-K
- 11/19/25 - Form 8-K
- 11/18/25 - Form 8-K
- HCWB's page on the SEC website